Genenta Science S.P.A. ADR (GNTA)

$1.88 +0.02 (1.08%)
Market Cap 36.95M
Revenue (ttm) 0.00
Net Income (ttm) -9.64M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin 0.00%
Debt to Equity Ratio 0.00
Volume 21,790
Avg Vol 832,838
Day's Range N/A - N/A
Shares Out 19.15M
Stochastic %K 60%
Beta 0.57
Analysts Strong Sell
Price Target $21.00

Company Profile

Genenta Science S.p.A., a clinical-stage biotechnology company, engages in the development of hematopoietic stem cell gene therapies for the treatment of solid tumors in Italy. Its lead product candidate is Temferon, which is in Phase 1/2a clinical trials for use in the treatment of glioblastoma multiforme in patients with unmethylated MGMT gene promoter. The company is developing Temferon for use in the treatment of other solid tumor indications, locally advanced hepatocellular carcinoma, and i...

Industry: Biotechnology
Sector: Healthcare
Phone: 39 02 26434681
Address:
Via Olgettina No. 58, Milan, Italy
KillerTrader
KillerTrader Nov. 26 at 2:51 PM
$GNTA reversal CONFIRMED
0 · Reply
KillerTrader
KillerTrader Nov. 25 at 2:52 PM
$GNTA long leg Doji reversal coming
0 · Reply
OpenOutcrier
OpenOutcrier Nov. 24 at 1:31 PM
$GNTA (+7.1% pre) Genenta (Nasdaq: GNTA) Temferon GBM data show 29% two-year survival and 3-year patient https://ooc.bz/l/85550
0 · Reply
KillerTrader
KillerTrader Nov. 24 at 12:36 PM
$GNTA waiting for real PR, update phase1/2. Kidney cancer
0 · Reply
mikesterz7
mikesterz7 Nov. 24 at 12:21 PM
$GNTA The company said that 25 patients have been treated with Temferon as of November 21, and 44% of glioblastoma multiforme patients have reached 18-month survival.
0 · Reply
StocktwitsNews
StocktwitsNews Nov. 24 at 11:37 AM
Genenta Stock Rises Pre-Market After Cell Therapy Improves Survival In Certain Tumor Patients $GNTA https://stocktwits.com/news/equity/markets/genenta-stock-rises-pre-market-after-cell-therapy-improves-survival-in-certain-tumor-patients/cL5b4qbREQb
0 · Reply
Thestocktraderhubzee
Thestocktraderhubzee Nov. 24 at 10:49 AM
WATCHLIST NOV 24 2025 $FUTU Futu Holdings shares are trading higher after Citigroup upgraded the stock from Neutral to Buy and maintained a $201 price target. $STM STMicroelectronics Unveiled New Smart Power Components That Let Home Appliances And Industrial Drives Leverage The Latest Gan (Gallium-nitride) Technology To Boost Energy Efficiency, Increase Performance, And Save Cost $PSFE Paysafe Announced Its Expanded Partnership With Boosteroid, The World's Largest Independent Cloud Gaming Provider $GNTA Genenta Science Announced An Update From Its Ongoing TEM-GBM Study In Newly Diagnosed Glioblastoma Multiforme (GBM) Patients With An Unmethylated MGMT (uMGMT) Gene Promoter $PLUG Plug Power To Hold Special Meeting Of Stockholders On January 15, 2026, To Ask Stockholders To Approve Amendment To Its Charter To Increase Authorized Common Stock From 1.5B To 3B Shares
0 · Reply
OTCshithead
OTCshithead Nov. 24 at 9:03 AM
$GNTA Genenta Reports Long-Term Survival Trends and Immune Findings in Brain Tumor (GBM) Trial 44% of patients have reached 18-month survival, compared to 38% reported in April. Two-year survival rate continues to be 29% and median overall survival remains at 17 months, both consistent with prior findings. For context, historical cohorts of uMGMT patients treated with standard of care typically show a two-year survival rate of approximately 14% and median overall survival of 13–15 months.
0 · Reply
KillerTrader
KillerTrader Nov. 21 at 4:53 PM
$GNTA have cash on hand for next 2 years, very tiny float
0 · Reply
KillerTrader
KillerTrader Nov. 21 at 4:50 PM
$GNTA we are in accomulation, pump will Come, with new on kidney cancer In 4q 2025
0 · Reply
Latest News on GNTA
Genenta Reports Long-Term Survival Trends and Immune Findings in Brain Tumor (GBM) Trial

Nov 24, 2025, 4:00 AM EST - 11 days ago

Genenta Reports Long-Term Survival Trends and Immune Findings in Brain Tumor (GBM) Trial

Genenta: Lentiviral Vector Technology Early Survival GBM Signal Warrants Buy Rating

Oct 27, 2025, 5:31 PM EDT - 5 weeks ago

Genenta: Lentiviral Vector Technology Early Survival GBM Signal Warrants Buy Rating

Genenta Announces Pricing of $15.0 Million Registered Direct Offering of American Depositary Shares

Oct 26, 2025, 8:30 PM EDT - 5 weeks ago

Genenta Announces Pricing of $15.0 Million Registered Direct Offering of American Depositary Shares

Genenta and Anemocyte Announce Strategic Partnership to Advance Off-The-Shelf LVV Plasmid DNA Production

Oct 24, 2025, 4:00 AM EDT - 6 weeks ago

Genenta and Anemocyte Announce Strategic Partnership to Advance Off-The-Shelf LVV Plasmid DNA Production

Genenta Announces Long-Term Follow-Up Observations in Brain Tumor (GBM) Study with Emerging Survival Signals

Jul 1, 2025, 5:00 AM EDT - 5 months ago

Genenta Announces Long-Term Follow-Up Observations in Brain Tumor (GBM) Study with Emerging Survival Signals

Genenta Science, SpA Announces Participation in the D. Boral Capital Inaugural Global Conference

May 8, 2025, 7:00 AM EDT - 7 months ago

Genenta Science, SpA Announces Participation in the D. Boral Capital Inaugural Global Conference

Genenta and Anemocyte announce a collaboration for the manufacturing of starting materials for cutting-edge cell-based therapies

May 7, 2025, 7:00 AM EDT - 7 months ago

Genenta and Anemocyte announce a collaboration for the manufacturing of starting materials for cutting-edge cell-based therapies

Genenta Showcases Strategic Vision at Premier Biotech Forum in Qatar

Apr 15, 2025, 5:00 AM EDT - 8 months ago

Genenta Showcases Strategic Vision at Premier Biotech Forum in Qatar

Genenta Announces €20 million ($21.9M) Financing To Expand Pipeline As Brain Tumor Trial Is Showing Promising Survival Rates

Mar 19, 2025, 9:28 AM EDT - 9 months ago

Genenta Announces €20 million ($21.9M) Financing To Expand Pipeline As Brain Tumor Trial Is Showing Promising Survival Rates

TOP ITALIAN AND U.S. LIFE SCIENCES EXECUTIVES AND ITALIAN GOVERNMENT LEADERS SHARED BUSINESS SUCCESS STORIES WITH INVESTORS AT "ITALY ON THE MOVE 2025" SIDE EVENT DURING J.P. MORGAN HEALTHCARE CONFERENCE

Jan 28, 2025, 8:01 AM EST - 11 months ago

TOP ITALIAN AND U.S. LIFE SCIENCES EXECUTIVES AND ITALIAN GOVERNMENT LEADERS SHARED BUSINESS SUCCESS STORIES WITH INVESTORS AT "ITALY ON THE MOVE 2025" SIDE EVENT DURING J.P. MORGAN HEALTHCARE CONFERENCE

Genenta Strengthens Agreement with AGC Biologics to Boost Cell Therapy Manufacturing

Jan 9, 2025, 6:00 AM EST - 11 months ago

Genenta Strengthens Agreement with AGC Biologics to Boost Cell Therapy Manufacturing

ITALIAN TRADE AGENCY TO HOST "ITALY ON THE MOVE 2025" SIDE EVENT DURING J.P. MORGAN HEALTHCARE CONFERENCE

Jan 8, 2025, 3:17 PM EST - 11 months ago

ITALIAN TRADE AGENCY TO HOST "ITALY ON THE MOVE 2025" SIDE EVENT DURING J.P. MORGAN HEALTHCARE CONFERENCE

Genenta's CEO to present at the U.S. Senate meeting on “Cross-Border Investments and Strategies in the Biotechnology Sector: A Transatlantic Perspective”

Oct 23, 2024, 7:00 AM EDT - 1 year ago

Genenta's CEO to present at the U.S. Senate meeting on “Cross-Border Investments and Strategies in the Biotechnology Sector: A Transatlantic Perspective”

Genenta Secures Approval for Innovative Trial for Metastatic Renal Cell Cancer

Oct 2, 2024, 6:30 AM EDT - 1 year ago

Genenta Secures Approval for Innovative Trial for Metastatic Renal Cell Cancer

Genenta Welcomes New Directors John L. Cantello, Lauren H.

May 6, 2024, 6:25 AM EDT - 1 year ago

Genenta Welcomes New Directors John L. Cantello, Lauren H.

Genenta Demonstrated Reprogramming of the Tumor Microenvironment in GBM Patients, Paving the Way for Innovative Treatments of Solid Tumors

Feb 8, 2024, 5:00 AM EST - 1 year ago

Genenta Demonstrated Reprogramming of the Tumor Microenvironment in GBM Patients, Paving the Way for Innovative Treatments of Solid Tumors

Genenta to Present at Upcoming Scientific and Investor Conferences

Sep 6, 2023, 7:00 AM EDT - 2 years ago

Genenta to Present at Upcoming Scientific and Investor Conferences

Genenta Announces Ongoing Clinical Trial Progress and Proposed Expansion in Solid Tumor Treatments

Jul 28, 2023, 3:00 AM EDT - 2 years ago

Genenta Announces Ongoing Clinical Trial Progress and Proposed Expansion in Solid Tumor Treatments

The European Commission Grants Orphan Drug Designation to Temferon™ for Treatment of Glioma

Jun 29, 2023, 7:00 AM EDT - 2 years ago

The European Commission Grants Orphan Drug Designation to Temferon™ for Treatment of Glioma

Genenta Announces Fiscal Year 2022 Financial Results and Annual Report on Form 20-F Filing

Apr 26, 2023, 7:00 AM EDT - 2 years ago

Genenta Announces Fiscal Year 2022 Financial Results and Annual Report on Form 20-F Filing

Genenta Announces Extension of License Agreement with Ospedale San Raffaele to All Solid Tumor Indications

Apr 3, 2023, 7:00 AM EDT - 2 years ago

Genenta Announces Extension of License Agreement with Ospedale San Raffaele to All Solid Tumor Indications

FDA Grants Orphan Drug Designation to Temferon for Treatment of Glioblastoma Multiforme

Mar 2, 2023, 6:45 AM EST - 3 years ago

FDA Grants Orphan Drug Designation to Temferon for Treatment of Glioblastoma Multiforme

Genenta Science and AGC Biologics Enter Development and Manufacturing Service Agreement

Feb 7, 2023, 7:00 AM EST - 3 years ago

Genenta Science and AGC Biologics Enter Development and Manufacturing Service Agreement

Genenta Update at SITC22 Indicates Potential for Anti-Tumor Immune System Reset after Temferon™ Treatment in Glioblastoma Patients

Nov 7, 2022, 8:05 AM EST - 3 years ago

Genenta Update at SITC22 Indicates Potential for Anti-Tumor Immune System Reset after Temferon™ Treatment in Glioblastoma Patients

Genenta Provides First Half 2022 Business Update and Financial Results

Oct 24, 2022, 7:30 AM EDT - 3 years ago

Genenta Provides First Half 2022 Business Update and Financial Results

Genenta to Present at Upcoming Investor Conferences

Sep 7, 2022, 7:00 AM EDT - 3 years ago

Genenta to Present at Upcoming Investor Conferences

AmCham Italy and Genenta Science Announce the Bowling Green Bull Initiative

Jul 25, 2022, 6:00 AM EDT - 3 years ago

AmCham Italy and Genenta Science Announce the Bowling Green Bull Initiative

Genenta to Present at Upcoming Scientific Congresses ASGCT, BTM, ASCO and EHA

May 13, 2022, 7:30 AM EDT - 3 years ago

Genenta to Present at Upcoming Scientific Congresses ASGCT, BTM, ASCO and EHA

Genenta Appoints Industry Veteran Tim Obara as Head of Business Development

May 9, 2022, 7:30 AM EDT - 3 years ago

Genenta Appoints Industry Veteran Tim Obara as Head of Business Development

Genenta Files Annual Report on Form 20-F for Fiscal Year 2021

May 4, 2022, 4:30 PM EDT - 3 years ago

Genenta Files Annual Report on Form 20-F for Fiscal Year 2021

Genenta Progresses to Higher Dosing Cohort in Temferon™ Phase 1/2a Clinical Trial in Glioblastoma Multiforme

May 4, 2022, 7:30 AM EDT - 3 years ago

Genenta Progresses to Higher Dosing Cohort in Temferon™ Phase 1/2a Clinical Trial in Glioblastoma Multiforme

Genenta ASGCT Clinical Data Highlights Temferon™ Biological Effects in Glioblastoma

May 2, 2022, 4:30 PM EDT - 3 years ago

Genenta ASGCT Clinical Data Highlights Temferon™ Biological Effects in Glioblastoma

Genenta Announces Nomination of Mark A. Sirgo as Chair

Apr 27, 2022, 7:30 AM EDT - 3 years ago

Genenta Announces Nomination of Mark A. Sirgo as Chair

Genenta to Host Expert Fireside Chat on Immuno Gene & Cell Therapy for Treatment of Solid Tumors

Apr 20, 2022, 7:30 AM EDT - 3 years ago

Genenta to Host Expert Fireside Chat on Immuno Gene & Cell Therapy for Treatment of Solid Tumors

Genenta Data Presentation at AACR to Describe On-Target Biological Activity of Temferon™ in Unmethylated Glioblastoma Multiforme

Mar 9, 2022, 7:46 AM EST - 4 years ago

Genenta Data Presentation at AACR to Describe On-Target Biological Activity of Temferon™ in Unmethylated Glioblastoma Multiforme

Genenta to Participate at Upcoming Investor Conferences

Feb 24, 2022, 7:30 AM EST - 4 years ago

Genenta to Participate at Upcoming Investor Conferences

Genenta Closes Its Upsized Initial Public Offering of American Depository Shares

Dec 17, 2021, 4:15 PM EST - 4 years ago

Genenta Closes Its Upsized Initial Public Offering of American Depository Shares

Genenta Announces Pricing of Upsized Initial Public Offering

Dec 14, 2021, 10:36 PM EST - 4 years ago

Genenta Announces Pricing of Upsized Initial Public Offering

KillerTrader
KillerTrader Nov. 26 at 2:51 PM
$GNTA reversal CONFIRMED
0 · Reply
KillerTrader
KillerTrader Nov. 25 at 2:52 PM
$GNTA long leg Doji reversal coming
0 · Reply
OpenOutcrier
OpenOutcrier Nov. 24 at 1:31 PM
$GNTA (+7.1% pre) Genenta (Nasdaq: GNTA) Temferon GBM data show 29% two-year survival and 3-year patient https://ooc.bz/l/85550
0 · Reply
KillerTrader
KillerTrader Nov. 24 at 12:36 PM
$GNTA waiting for real PR, update phase1/2. Kidney cancer
0 · Reply
mikesterz7
mikesterz7 Nov. 24 at 12:21 PM
$GNTA The company said that 25 patients have been treated with Temferon as of November 21, and 44% of glioblastoma multiforme patients have reached 18-month survival.
0 · Reply
StocktwitsNews
StocktwitsNews Nov. 24 at 11:37 AM
Genenta Stock Rises Pre-Market After Cell Therapy Improves Survival In Certain Tumor Patients $GNTA https://stocktwits.com/news/equity/markets/genenta-stock-rises-pre-market-after-cell-therapy-improves-survival-in-certain-tumor-patients/cL5b4qbREQb
0 · Reply
Thestocktraderhubzee
Thestocktraderhubzee Nov. 24 at 10:49 AM
WATCHLIST NOV 24 2025 $FUTU Futu Holdings shares are trading higher after Citigroup upgraded the stock from Neutral to Buy and maintained a $201 price target. $STM STMicroelectronics Unveiled New Smart Power Components That Let Home Appliances And Industrial Drives Leverage The Latest Gan (Gallium-nitride) Technology To Boost Energy Efficiency, Increase Performance, And Save Cost $PSFE Paysafe Announced Its Expanded Partnership With Boosteroid, The World's Largest Independent Cloud Gaming Provider $GNTA Genenta Science Announced An Update From Its Ongoing TEM-GBM Study In Newly Diagnosed Glioblastoma Multiforme (GBM) Patients With An Unmethylated MGMT (uMGMT) Gene Promoter $PLUG Plug Power To Hold Special Meeting Of Stockholders On January 15, 2026, To Ask Stockholders To Approve Amendment To Its Charter To Increase Authorized Common Stock From 1.5B To 3B Shares
0 · Reply
OTCshithead
OTCshithead Nov. 24 at 9:03 AM
$GNTA Genenta Reports Long-Term Survival Trends and Immune Findings in Brain Tumor (GBM) Trial 44% of patients have reached 18-month survival, compared to 38% reported in April. Two-year survival rate continues to be 29% and median overall survival remains at 17 months, both consistent with prior findings. For context, historical cohorts of uMGMT patients treated with standard of care typically show a two-year survival rate of approximately 14% and median overall survival of 13–15 months.
0 · Reply
KillerTrader
KillerTrader Nov. 21 at 4:53 PM
$GNTA have cash on hand for next 2 years, very tiny float
0 · Reply
KillerTrader
KillerTrader Nov. 21 at 4:50 PM
$GNTA we are in accomulation, pump will Come, with new on kidney cancer In 4q 2025
0 · Reply
mcewing
mcewing Nov. 21 at 4:48 PM
$GNTA someone should file SEC regarding Maxim and this obvious PUMP and DUMP.
0 · Reply
KillerTrader
KillerTrader Nov. 21 at 4:47 PM
$GNTA double down 1,44 , average 1,62… waiting for Update Study Evaluating Temferon in Patients with Glioblastoma & Unmethylated MGMT (TEM-GBM)
0 · Reply
KillerTrader
KillerTrader Nov. 21 at 4:45 PM
$GNTA last scroll down ,STOP LOSS HUNTERS at work, be careful with Sl 🚨🚨
0 · Reply
theBigDollarski
theBigDollarski Nov. 21 at 4:30 PM
$GNTA unreal....couldn't even get a shot at the shares offered in the 1.40's.
0 · Reply
mcewing
mcewing Nov. 21 at 4:07 PM
$GNTA max pain here
0 · Reply
KillerTrader
KillerTrader Nov. 20 at 5:58 PM
$GNTA In
0 · Reply
The_Big_Long
The_Big_Long Nov. 19 at 7:03 PM
$GNTA somebody is gonna spot this and start buying it up real quick and then it’s gonna really start moving… I’m in. ! $NVDA
1 · Reply
The_Big_Long
The_Big_Long Nov. 19 at 6:49 PM
$GNTA Ohhhh yeah this looks like it’s ready for a nice pump .. dropped 15K in !
1 · Reply
mcewing
mcewing Nov. 18 at 4:08 PM
$GNTA mostly out....this stock is dead. Left a small position.
1 · Reply
ForkMAN
ForkMAN Nov. 13 at 3:53 PM
$GNTA yes, due for a push back up to that new issure price of 3.50.
0 · Reply
InvestingCat
InvestingCat Nov. 12 at 10:39 AM
$GNTA about to get pumped more than $SLRX, don't miss out
0 · Reply
theBigDollarski
theBigDollarski Nov. 11 at 6:18 PM
$GNTA I'm in..
0 · Reply